Table 4.
Prevalence of PIMs and PPOs identified by POPI in hospital
| Criteria | No. of PIMs | No. of patients with the targeted disorders* | % of PIMs in patients with the targeted disorders | |
| PIMs | 541 | 7304 | 7.4% | |
| Various illnesses | 3 | 64 | 4.6% | |
| AI-6 | Opiates to treat migraine attacks | 3 | 64 | 4.6% |
| Digestive disorders | 56 | 1956 | 2.8% | |
| EI-2 | Domperidone | 28 | 1956 | 1.4% |
| FI-3 | The use of diosmectite (Smecta) in combination with another medication. | 27 | 1956 | 1.4% |
| EI-1 | Metoclopramide | 1 | 1956 | <0.1% |
| ENT-Pulmonary disorders | 472 | 5163 | 9.1% | |
| II-4 | Antibiotics to treat acute suppurative otitis media and so on. | 2 | 7 | 28.6% |
| II-2 | Antibiotic treatment for a sore throat, without a positive RDT. | 23 | 160 | 14.4% |
| II-9 | Ear drops in the event of acute otitis media. | 86 | 1083 | 7.9% |
| HI-1 | Beta2 agonist, corticosteroids to treat an infant’s first case of bronchiolitis. | 25 | 386 | 6.4% |
| II-5 | Corticosteroids to treat acute suppurative otitis media and so on. | 190 | 3616 | 5.2% |
| II-1 | An antibiotic other than amoxicillin as a first-line treatment. | 59 | 1259 | 4.7% |
| JI-1 | H1-antagonist to treat asthma. | 9 | 802 | 1.1% |
| II-8 | Tenoate etanolamine (Rhinotrophyl) and other nasal antiseptics. | 21 | 2455 | 0.8% |
| II-3 | Antibiotics for nasopharyngitis. | 26 | 3444 | 0.7% |
| GI-3 | Alimemazine (Theralene), oxomemezine (Toplexil) and so on. | 18 | 2585 | 0.7% |
| JI-2 | Cough suppressants to treat asthma. | 5 | 802 | 0.6% |
| HI-2 | H1-antagonists, cough suppressants and so on to treat bronchiolitis. | 2 | 386 | 0.5% |
| II-7 | H1-antagonists with sedative or atropine-like effects. | 4 | 2585 | 0.2% |
| GI-2 | Mucolytics drugs, mucokinetics drugs or helicidine before 2 years of age. | 1 | 2585 | <0.1% |
| II-6 | Nasal or oral decongestant and so on. | 1 | 2455 | <0.1% |
| Dermatological disorders | 10 | 100 | 10% | |
| OI-1 | A combination of locally applied and orally administered antibiotics. | 9 | 32 | 28.1% |
| PI-2 | Topical agents containing acyclovir administered to a child under 6 years of age. | 1 | 68 | 1.5% |
| No. of PPO | No. of patients with the targeted disorders* | % of PPOs in patients with the targeted disorders | ||
| PPOs | 424 | 4508 | 9.4% | |
| Digestive disorders | 372 | 1956 | 19.0% | |
| EO-1 | Oral rehydration solution in the event of vomiting. | 135 | 313 | 43.1% |
| FO-1 | Oral rehydration solution in the event of diarrhoea. | 237 | 1643 | 14.4% |
| ENT-Pulmonary disorders | 51 | 1469 | 3.5% | |
| HO-1 | 0.9% NaCl to relieve nasal congestion and so on. | 38 | 386 | 9.8% |
| IO-2 | Acetaminophen combined with antibiotic treatment for ear infections and so on. | 13 | 1083 | 1.3% |
| Dermatological disorders | 1 | 3 | 33.3% | |
| NO-2 | Griseofulvin taken during a meal containing a moderate amount of fat. | 1 | 3 | 33.3% |
*The number of patients with the targeted disorder corresponds to patients with clinical situations at risk of PIM or PPO.
%, Percentage calculated by the number of PIMs or PPO detected from the total number of analyzable cases; ENT, ear, nose and throat; PIMs, potentially inappropriate medicines; PPOs, potentially prescribing omissions; RDT, rapid diagnostic test.